PT Kalbe Farma Tbk. carries a market capitalization of 32.58T, placing it among publicly traded companies globally. Its enterprise value stands at 41.09T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 32.58T |
| Enterprise Value | 41.09T |
PT Kalbe Farma Tbk. currently has 45.25B shares outstanding.
| Shares Outstanding | 45.25B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
PT Kalbe Farma Tbk. trades at a trailing price-to-earnings ratio of 14.83. The price-to-sales ratio is 1.61, and the price-to-book ratio stands at 1.66.
| PE Ratio | 14.83 |
| PS Ratio | 1.61 |
| PB Ratio | 1.66 |
| P/TBV Ratio | 1.87 |
| P/FCF Ratio | 75.48 |
| P/OCF Ratio | N/A |
On an enterprise value basis, PT Kalbe Farma Tbk. trades at an EV/EBITDA multiple of 11.26 and an EV/FCF ratio of 68.73. The EV/Sales ratio of 1.51 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 11.26 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.51 |
| EV / EBITDA | 11.26 |
| EV / EBIT | 11.26 |
| EV / FCF | 68.73 |
PT Kalbe Farma Tbk. maintains a current ratio of 3.56, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.18, indicating moderate leverage, while an interest coverage ratio of 175.74 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.56 |
| Quick Ratio | 0.81 |
| Debt / Equity | 1.18 |
| Debt / EBITDA | 0.08 |
| Interest Coverage | 175.74 |
PT Kalbe Farma Tbk. posts a return on equity of 11.63 and a return on invested capital of 10.90.
| Return on Equity (ROE) | 11.63 |
| Return on Assets (ROA) | 9.46 |
| Return on Invested Capital (ROIC) | 10.90 |
| Return on Capital Employed (ROCE) | 10.60 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.18 |
Over the trailing twelve months, PT Kalbe Farma Tbk. has paid 816.83B in income taxes, reflecting an effective tax rate of 21.29.
| Income Tax | 816.83B |
| Effective Tax Rate | 21.29 |
PT Kalbe Farma Tbk.'s stock has declined approximately -55% over the past 52 weeks. The 50-day moving average sits at 897.60, while the 200-day moving average is 1,099.50.
| Beta (5Y) | N/A |
| 52-Week Price Change | -55% |
| 50-Day Moving Average | 897.60 |
| 200-Day Moving Average | 1,099.50 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, PT Kalbe Farma Tbk. generated 27.25T in revenue and converted that into 2.96T in net income, yielding earnings per share of 66.74. EBITDA reached 3.65T, while operating income came in at 3.65T.
| Revenue | 27.25T |
| Gross Profit | 13.91T |
| Operating Income | 3.65T |
| Pretax Income | 3.84T |
| Net Income | 2.96T |
| EBITDA | 3.65T |
| EBIT | 3.65T |
| Earnings Per Share (EPS) | 66.74 |
PT Kalbe Farma Tbk. holds 4.55T in cash and equivalents against 304.26B in total debt, resulting in a net debt position of -4.14T. Total book value stands at 26.44T, with working capital of 14.31T providing operational flexibility.
| Cash & Cash Equivalents | 4.55T |
| Total Debt | 304.26B |
| Net Debt | -4.14T |
| Equity (Book Value) | 26.44T |
| Book Value Per Share | 584.19 |
| Working Capital | 14.31T |
After subtracting -581.54B in capital expenditures, free cash flow totaled -581.54B - equivalent to -12.85 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -581.54B |
| Free Cash Flow | -581.54B |
| FCF Per Share | -12.85 |
PT Kalbe Farma Tbk. operates with a gross margin of 18.34, reflecting its pricing power and cost economics. The operating margin of 13.39 and net profit margin of 10.87 provide insight into operational efficiency.
| Gross Margin | 18.34 |
| Operating Margin | 13.39 |
| Pretax Margin | 14.08 |
| Profit Margin | 10.87 |
| EBITDA Margin | 13.39 |
The company's payout ratio of 0.00 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.00 |
| Dividend Yield | N/A |
| Payout Ratio | 0.00 |
| Shareholder Yield | 4.81 |
| FCF Yield | 1.32 |
PT Kalbe Farma Tbk.'s most recent stock split took place on October 8, 2012 with a 1:5 split ratio.
| Last Split Date | 10/8/2012 |
| Split Ratio | 1:5 |
PT Kalbe Farma Tbk. posts an Altman Z-Score of 7.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.34 |